Clinical trial
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
NCT00420784 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00420784 |
|---|---|
| Title | A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3) |
| Official title | A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Matching Placebo |
| Enrollment | 465 |
| Start date | Feb 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Jan 11, 2007 |
| Last update posted | Aug 5, 2014 |
| Countries | Canada, Germany, Netherlands, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: